Codeine risky for kids after certain surgeries, FDA says

Codeine risky for kids after certain surgeries, FDA says
10 deaths, 3 overdoses reported following removal of tonsils or adenoids.

(HealthDay)—Children who are given codeine for pain relief after surgery to remove tonsils or adenoids are at risk for overdose and death, U.S. health officials said Thursday.

The U.S. said a new boxed warning—the agency's strongest caution—will be added to the labels of codeine-containing products to warn about this danger.

The FDA strongly recommends against the use of codeine to manage pain in children after surgery to remove or , and suggests that doctors use an alternate . The agency also said parents and caregivers need to be aware of the risks and ask for a different if their children are prescribed codeine after having their tonsils or adenoids removed.

Codeine is an opioid (narcotic) medication used to treat mild to and is often prescribed to children after tonsil or adenoid removal. However, some children have died after being given codeine within the recommended dose range.

In August 2012, the FDA warned about the danger in children who are "ultra-rapid metabolizers" of codeine, which means their liver converts codeine to morphine in higher-than-normal amounts. High levels of morphine can result in potentially fatal breathing problems.

Since then, a safety review by the FDA identified 10 deaths and three associated with codeine that occurred among children in the United States between 1969 and May 2012. Many of these children were recovering from surgery to remove tonsils or adenoids.

All of the children, aged 21 months to 9 years old, received doses of codeine within the normal dose range. Signs of morphine overdose developed within one to two days after the children began taking codeine, the FDA said in an agency news release.

Codeine is available by prescription either alone or in combination with acetaminophen and aspirin, and in some cough and .

When prescribed to treat pain, codeine should not be given on a fixed schedule, but only when a child needs relief from pain. They should never receive more than six doses in a day, the FDA said.

Children receiving codeine for pain should be closely monitored for signs of morphine overdose. These include: unusual sleepiness, such as being difficult to wake up; confusion or disorientation; breathing problems; and blueness on the lips or around the mouth.

Parents and caregivers who notice such signs should stop giving codeine and immediately take the child to an emergency department or call 911, said Dr. Bob Rappaport, director of the division of anesthesia, analgesia and addiction products in FDA's Center for Drug Evaluation and Research.

More information: The U.S. National Library of Medicine has more about codeine.

add to favorites email to friend print save as pdf

Related Stories

US warns about use of codeine in children

Aug 15, 2012

(AP) — The U.S. Food and Drug Administration warned physicians and caregivers on Wednesday about the risks of giving the pain reliever codeine to children who have just had surgery to treat obstructive sleep apnea.

It's time to phase out codeine

Oct 04, 2010

It is time to phase out the use of codeine as a pain reliever because of its significant risks and ineffectiveness as an analgesic, states an editorial in CMAJ (Canadian Medical Association Journal).

Codeine not safe for all breastfeeding moms and their babies

Aug 20, 2008

Using pain treatments which contain codeine may be risky for some breastfeeding mothers, according to researchers at The University of Western Ontario, and the Hospital for Sick Children (SickKids) in Toronto. Lead author ...

Warning over codeine use after tonsillectomy

Aug 19, 2009

A report out of The University of Western Ontario, published in the New England Journal of Medicine, warns the use of codeine to treat pain following a tonsillectomy could prove fatal for some children. Dr. Gideon Koren, ...

Recommended for you

Supercomputers link proteins to drug side effects

21 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments